Simcere Zaiming, announced that their new anti-EGFR antibody treatment, Enlituo®, has been officially approved for sale by the China National Medical Administration.
The U.S. Food and Drug Administration (FDA) approved Ripretinib on May 15, 2020, for the treatment of advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with three or more kinase inhibitors, including imatinib.
The FDA granted approval for capmatinib on May 6, 2020. Capmatinib is used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed with surgery.